These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
567 related articles for article (PubMed ID: 12851836)
1. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Omura K Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836 [TBL] [Abstract][Full Text] [Related]
2. [5-fluorouracil and dihydropyrimidine dehydrogenase]. Kubota T Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775 [TBL] [Abstract][Full Text] [Related]
3. 5-fluorouracil and dihydropyrimidine dehydrogenase. Kubota T Int J Clin Oncol; 2003 Jun; 8(3):127-31. PubMed ID: 12851835 [TBL] [Abstract][Full Text] [Related]
4. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations]. Ogura K Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518 [TBL] [Abstract][Full Text] [Related]
5. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer. Terashima M; Fujiwara H; Takagane A; Abe K; Irinoda T; Nakaya T; Yonezawa H; Oyama K; Saito K; Kanzaki N; Ohtani S; Nemoto T; Hoshino Y; Kogure M; Gotoh M Gastric Cancer; 2003; 6 Suppl 1():71-81. PubMed ID: 12775024 [TBL] [Abstract][Full Text] [Related]
6. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Mattison LK; Soong R; Diasio RB Pharmacogenomics; 2002 Jul; 3(4):485-92. PubMed ID: 12164772 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601 [TBL] [Abstract][Full Text] [Related]
8. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy. Amstutz U; Farese S; Aebi S; Largiadèr CR J Exp Clin Cancer Res; 2008 Oct; 27(1):54. PubMed ID: 18937829 [TBL] [Abstract][Full Text] [Related]
9. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer]. Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867 [TBL] [Abstract][Full Text] [Related]
10. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. van Kuilenburg AB Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568 [TBL] [Abstract][Full Text] [Related]
11. [Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase]. Lazar A; Jetter A Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1501-4. PubMed ID: 18597209 [TBL] [Abstract][Full Text] [Related]
14. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene. Ofverholm A; Arkblad E; Skrtic S; Albertsson P; Shubbar E; Enerbäck C Clin Biochem; 2010 Feb; 43(3):331-4. PubMed ID: 19822137 [TBL] [Abstract][Full Text] [Related]
15. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. van Kuilenburg AB; Haasjes J; Richel DJ; Zoetekouw L; Van Lenthe H; De Abreu RA; Maring JG; Vreken P; van Gennip AH Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223 [TBL] [Abstract][Full Text] [Related]
16. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks]. Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921 [TBL] [Abstract][Full Text] [Related]
17. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH Int J Cancer; 2002 Sep; 101(3):253-8. PubMed ID: 12209976 [TBL] [Abstract][Full Text] [Related]
18. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. Terashima M; Irinoda T; Fujiwara H; Nakaya T; Takagane A; Abe K; Yonezawa H; Oyama K; Inaba T; Saito K; Takechi T; Fukushima M Anticancer Res; 2002; 22(2A):761-8. PubMed ID: 12014648 [TBL] [Abstract][Full Text] [Related]
19. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil]. Ostapowicz A; Dołegowska B Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991 [TBL] [Abstract][Full Text] [Related]
20. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation. Fischel JL; Etienne MC; Spector T; Formento P; Renée N; Milano G Clin Cancer Res; 1995 Sep; 1(9):991-6. PubMed ID: 9816071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]